

1 **Antibody titers measured by commercial assays are correlated with neutralizing**  
2 **antibody titers calibrated by international standards**

3 Yu-An Kung<sup>a,\*</sup>, Chung-Guei Huang<sup>c,d,\*</sup>, Sheng-Yu Huang<sup>a,\*</sup>, Kuan-Ting Liu<sup>a,b,\*</sup>, Peng-  
4 Nien Huang<sup>a,c</sup>, Kar-Yee Yu<sup>a,b</sup>, Shu-Li Yang<sup>c</sup>, Chia-Pei Chen<sup>c</sup>, Ching-Yun Cheng<sup>c</sup>,  
5 Yuch-Te Lin<sup>a,b</sup>, Yen-Chin Liu<sup>a</sup>, Guang-Wu Chen,<sup>a,c,f,g,#</sup> Shin-Ru Shih<sup>a,c,d,h,#</sup>

6

7 <sup>a</sup> Research Center for Emerging Viral Infections, College of Medicine, Chang Gung  
8 University, Taoyuan, Taiwan

9 <sup>b</sup> Graduate Institute of Biomedical Science, College of Medicine, Chang Gung  
10 University, Taoyuan, Taiwan

11 <sup>c</sup> Department of Laboratory Medicine, Linkou Chang Gung Memorial Hospital,  
12 Taoyuan, Taiwan

13 <sup>d</sup> Department of Medical Biotechnology and Laboratory Science, College of Medicine,  
14 Chang Gung University, Taoyuan, Taiwan

15 <sup>e</sup> Division of Infectious Diseases, Department of Pediatrics, Linkou Chang Gung  
16 Memorial Hospital, Taoyuan, Taiwan

17 <sup>f</sup> Artificial Intelligence Research Center, Chang Gung University, Taoyuan, Taiwan

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

18 <sup>g</sup> Department of Computer Science and Information Engineering, School of Electrical

19 and Computer Engineering, College of Engineering, Chang Gung University, Taoyuan,

20 Taiwan

21 <sup>h</sup> Research Center for Chinese Herbal Medicine, Research Center for Food and

22 Cosmetic Safety, and Graduate Institute of Health Industry Technology, College of

23 Human Ecology, Chang Gung University of Science and Technology, Taoyuan,

24 Taiwan

25

26 <sup>#</sup> Corresponding author

27 Guang-Wu Chen, Ph.D. (E-mail: [gwchen@mail.cgu.edu.tw](mailto:gwchen@mail.cgu.edu.tw))

28 Department of Computer Science and Information Engineering, Chang Gung

29 University, Taiwan

30 Mailing address: No.259, Wenhua 1st Rd., Guishan Dist., Taoyuan City, Taiwan

31 Phone: +886-3-2118800 ext.3368

32

33 Shin-Ru Shih, Ph.D. (E-mail: [srshih@mail.cgu.edu.tw](mailto:srshih@mail.cgu.edu.tw))

34 Research Center for Emerging Viral Infections, Chang Gung University, Taoyuan,

35 Taiwan

36 Mailing address: No.259, Wenhua 1st Rd., Guishan Dist., Taoyuan City, Taiwan

37 Phone: +886-3-2118800 ext.5497

38 \* These authors contributed equally to the study.

39 **Running title: Correlation between IU value of NAb and Ab titer**

40 **Abstract**

41 The World Health Organization (WHO) has highlighted the importance of an  
42 international standard (IS) for SARS-CoV-2 neutralizing antibody titer detection, with  
43 the aim of calibrating different diagnostic techniques. In this study, IS was applied to  
44 calibrate neutralizing antibody titers (IU/mL) and binding antibody titers (BAU/mL) in  
45 response to SARS-CoV-2 vaccines. Serum samples were collected from participants  
46 receiving the Moderna (n = 20) and Pfizer (n = 20) vaccines at three time points: pre-  
47 vaccination, after one dose, and after two doses. We obtained geometric mean titers of  
48 1404.16 and 928.75 IU/mL for neutralizing antibodies after two doses of the Moderna  
49 and Pfizer vaccines, respectively. These values provide an important baseline for  
50 vaccine development and the implementation of non-inferiority trials. We also  
51 compared three commercially available kits from Roche, Abbott, and MeDiPro for the  
52 detection of COVID-19 antibodies based on binding affinity to S1 and/or RBD. Our  
53 results demonstrated that antibody titers measured by commercial assays are highly  
54 correlated with neutralizing antibody titers calibrated by IS.

55

## 56 **Introduction**

57 Identifying immune correlates of protection against SARS-CoV-2 infection is  
58 challenging. Neutralizing antibody titer is not the only determinant of vaccine efficacy;  
59 however, the neutralization level is highly predictive of immune protection (1-3).  
60 Moreover, the detection of neutralizing antibody titers is feasible in many laboratories.  
61 Several methods have been developed to measure neutralizing antibody titers in  
62 convalescent serum or vaccinated serum, such as plaque reduction assays, focus  
63 reduction assays, microneutralization assays using real viruses, and pseudovirus assays  
64 (4, 5). These assays differ substantially, including variation in protocols for similar  
65 assay types and variation among laboratories (6, 7).

66 For calibration, the establishment of international standards (IS) for SARS-CoV-  
67 2 neutralizing antibody titer detection is a key goal of the World Health Organization  
68 (WHO). Various standards, such as 20/130 and 20/136 (provided by National Institute  
69 for Biological Standards and Control [NIBSC]), are widely used to establish a baseline  
70 for comparing neutralizing antibody titers from different datasets (different laboratories,  
71 protocols, assays, etc.) (6). An IS is based on pooled human plasma from convalescent  
72 patients (8). For different pooled cohorts, different standard sera are obtained, each with  
73 predetermined international units (IU) for the conversion of neutralizing antibody titers,  
74 enabling immunogenicity characteristics to be correctly compared across laboratories

75 and vaccine developers. Although many laboratories have applied IU to present  
76 neutralizing antibody titers in the serum of patients with COVID-19 or vaccinated  
77 individuals, reference data are insufficient.

78 Furthermore, neutralization tests using real viruses at biosafety level 3 (BSL-3)  
79 laboratories are laborious and time-consuming. Binding assays based on the anti-spike  
80 protein or anti-receptor binding domain (RBD) are widely used to measure neutralizing  
81 antibodies (9-11). However, the correlation between antibody titers from binding assays  
82 (binding antibody unit, BAU) and neutralizing titers (IU) has not been clearly  
83 established.

84 In this study, 120 serum samples from 40 total subjects were analyzed (20 subjects  
85 receiving Moderna vaccines and 20 subjects receiving the Pfizer vaccines) before  
86 vaccination, after the first dose, and after the second dose to estimate the correlation  
87 between titers estimated by a microneutralization assay using real viruses in a BSL-3  
88 laboratory (IU/mL) and antibody titers measured by anti-S1 and anti-RBD enzyme-  
89 linked immunosorbent assay (ELISA) (BAU/mL). Several promising vaccine  
90 candidates have undergone different phases of clinical trials (12). Our results provide  
91 useful information for comparisons of neutralizing antibody titers with those of other  
92 widely used vaccines and for non-inferiority trials.

93

94 **Materials and Methods**

95 **Serum samples collection**

96 A total of 120 COVID-19 vaccinated sera were purchased from Access Biologicals  
97 (Vista, CA, USA). The serum samples were collected and followed by protocol SDP-  
98 003, *Human Biological Specimens Collection*, data September 22, 2017 and the  
99 qualifications of Principle Investigator (Robert Pyrtle, M.D.) were reviewed and  
100 approved by Diagnostics Investigational Review Board (Cummerquid, Massachusetts,  
101 USA). The protocol SDP-003 will expire on May 3, 2022. The collection dates of the  
102 sera were between February 25, 2021 to April 29, 2021. The serum from 20 individuals  
103 vaccinated with Moderna mRNA-1273 and 20 individuals vaccinated with Pfizer  
104 BNT162b2 were collected before vaccination, after the first dose, and after the second  
105 dose. The ages of the vaccinated participants are between 22 to 69 years old.

106

107 **Cell culture and virus**

108 African green monkey kidney (Vero E6) cells (CRL-1586) were purchased from the  
109 American Type Culture Collection (ATCC, Bethesda, MD, USA) and maintained in  
110 Dulbecco's modified Eagle's medium (DMEM; Gibco, Waltham, MA, USA)  
111 containing 10% fetal bovine serum (FBS; Gibco) at 37°C. Severe acute respiratory

112 syndrome coronavirus 2 isolate SARS-CoV-2/human/TWN/CGMH-CGU-01/2020

113 was used in the live virus microneutralization assay.

114

#### 115 **Live virus microneutralization assay**

116 Vero E6 cells ( $2 \times 10^4$  cells per well) were seeded in a 96-well plate and incubated at

117 37°C for 24 h. The medium was replaced with 100  $\mu$ L of fresh DMEM containing 2%

118 FBS. The live virus microneutralization assay was performed in a BSL-3 laboratory

119 using the SARS-CoV-2/human/TWN/CGMH-CGU-01/2020 strain. All serum samples

120 were heat-inactivated at 56°C for 30 min and then 2-fold serially diluted in DMEM

121 (Gibco) without FBS. From a starting dilution of 1:8 for each sample, ten 2-fold

122 dilutions were performed for a final dilution of 1:8192. Each serum sample was

123 incubated with 100 50% tissue culture infectious doses (100 TCID<sub>50</sub>) of SARS-CoV-

124 2 at 37°C for 1 h prior to infection with Vero E6 cells. Add 100  $\mu$ L of the virus-serum

125 mixtures at each dilution to a 96-well plate containing the confluent Vero E6 monolayer.

126 After infected cells were incubated at 37°C for 5 days, they were fixed with 10%

127 formaldehyde and stained with crystal violet. The neutralization titer was calculated as

128 the logarithm of the 50% end point using the Reed–Muench method based on the

129 presence or absence of cytopathic effects. Each serum sample was tested in four

130 replicates. Geometric mean titers (GMTs) were calculated with 95% confidence  
131 intervals (CIs) using GraphPad Prism version 8 (GraphPad Software, Inc., CA, USA).

132

### 133 **ELISA**

134 For indirect ELISA, a 96-well plate was coated with 2 µg/mL S1, RBD, and N protein  
135 (Sino Biological, Beijing, China) diluted in phosphate-buffered saline and incubated  
136 overnight at 4°C. Each well was blocked with 300 µL of StartingBlock™ T20 blocking  
137 buffer (Thermo Fisher Scientific, Waltham, MA, USA) for 1 h at 37°C. Serum from  
138 vaccinated donors or NIBSC 20/136 standard was diluted in blocking buffer, and 100  
139 µL of the sample was added to a 96-well plate, followed by incubation for 1 h at 37°C.  
140 After washing, horseradish peroxidase (HRP)-tagged anti-human antibodies (Abcam,  
141 Cambridge, UK), diluted 1:10,000 in blocking buffer, were added to the wells (100  
142 µL/well), and the plate was incubated for 1 h at 37°C. Samples with N antibodies were  
143 incubated for 30 min at 37°C. The chromogenic reagent 3,3',5,5'-tetramethylbenzidine  
144 (TMB) was mixed with an equal volume of Color A and B (R&D Systems, Minneapolis,  
145 MN, USA). The TMB reaction time for S1 and RBD ELISA was 5 min and for N  
146 protein ELISA was 10 min. After the reaction, stop solution (R&D Systems) was added  
147 to the wells, and the absorbance was measured immediately at 450 nm using a Synergy  
148 2 Microplate Reader (Bio-Tek, Winooski, VT, USA).



149 **Serologic assay**

150 Each serum sample was analyzed by the MeDiPro SARS-CoV-2 antibody ELISA,  
151 Roche Elecsys<sup>®</sup> Anti-SARS-CoV-2 S assay, and Abbott AdviseDx SARS-CoV-2 IgG  
152 II assay, according to the manufacturers' instructions. The MeDiPro SARS-CoV-2  
153 antibody ELISA detected antibodies against S1 and RBD, and values <34.47 IU/mL  
154 were considered negative. The electrochemiluminescence immunoassay (ECLIA) (i.e.,  
155 Roche Elecsys Anti-SARS-CoV-2 S assay) was used for the detection of antibodies  
156 against the RBD of S protein; <0.80 U/mL was considered negative and  $\geq 0.80$  U/mL  
157 was considered positive for anti-SARS-CoV-2 S protein. The Abbott AdviseDx SARS-  
158 CoV-2 IgG II assay is a chemiluminescent microparticle immunoassay (CMIA) for the  
159 detection of IgG antibodies to the RBD of S protein; the cut-off value was 50.0 AU/mL.

160

161 **WHO international standard unit (IU) conversion**

162 WHO IS sera (20/130, 20/136, and 20/268) were obtained from NIBSC. The 50%  
163 neutralization titer (NT<sub>50</sub>) values for WHO IS sera were determined by a live virus  
164 microneutralization assay (Supplementary Table 1). Each standard serum sample was  
165 tested in duplicate, except 20/130.

166

167

168 **Statistical analysis**

169 Statistical analyses were performed using GraphPad Prism version 8 (GraphPad

170 Software, Inc., CA, USA). Pearson's correlation coefficients ( $r$ ) were used to determine

171 the correlation between the titers obtained by the different serological assays and the

172 live SARS-CoV-2 NT assay. Statistical significance was set at  $P < 0.05$ .

173

174 **Results**

175 The neutralizing antibody titer is important for evaluating protection against viral  
176 infection after vaccination. Dynamic neutralizing antibody titers were observed in  
177 individuals who had been fully vaccinated. In detail, we obtained serum samples from  
178 20 individuals vaccinated with Moderna mRNA-1273 and 20 individuals vaccinated  
179 with Pfizer BNT162b2. For each of these 40 individuals, serum samples were collected  
180 before the first dose, 24 days after the first dose from Moderna or 14 days after the first  
181 dose from Pfizer, and 14 days after the second dose. A total of 120 serum samples were  
182 tested to determine neutralizing antibody titers by a live SARS-CoV-2 virus  
183 microneutralization assay. We obtained the NT<sub>50</sub> values that represent 50% protection  
184 against SARS-CoV-2-induced cell death. As expected, the neutralizing antibody titers  
185 increased after the first and second doses of the Moderna and Pfizer vaccines (Figure  
186 1A). The NT<sub>50</sub> values for the WHO IS for anti-SARS-CoV-2 immunoglobulin (obtained  
187 from NIBSC) were also determined by a live virus neutralization assay (Supplementary  
188 Table 1), with linear regression defining the conversion of NT<sub>50</sub> values to IU/mL, as  
189 shown in Figure 1B. The GMTs are also shown in Figure 1, illustrating the observed  
190 increases. The GMT increased from 157.6 to 1404.16 IU/mL and from 348.83 to 928.75  
191 IU/mL for Moderna and Pfizer vaccines, respectively. These GMT values provide a  
192 reference for non-inferiority tests of candidate vaccines.

193           Although the live virus neutralization assay is the gold standard for determining  
194 neutralizing antibody titers, the operation is time-consuming and requires a BSL-3  
195 laboratory. We developed binding assays to detect anti-S1, anti-RBD, and anti-N  
196 antibodies, followed by NIBSC 20/136 (WHO IS) for conversion to BAU/mL (Figure  
197 2). Increases in anti-S1 and anti-RBD antibodies were observed after the first and  
198 second doses (Figure 2A and B). Interestingly, anti-N antibodies were detected in a few  
199 individuals pre- and post-vaccination, suggesting that the individuals had COVID-19  
200 before or after vaccination.

201           To evaluate whether our binding assay based on anti-S1 or anti-RBD in BAU/mL  
202 reflects neutralizing antibody titers in IU/mL, the correlation between the two values  
203 was determined, as shown in Figure 2C. Both the S1 and RBD antibody titers were  
204 highly correlated with the NT titers ( $r = 0.9040$  and  $0.9298$ , respectively), suggesting  
205 that the binding assays based on anti-S1 or RBD can be used as surrogates to measure  
206 neutralizing antibodies.

207           All 120 serum samples were tested by commercial serological assays, including  
208 the MeDiPro SARS-CoV-2 antibody ELISA, Roche Elecsys<sup>®</sup> Anti-SARS-CoV-2 S,  
209 and Abbott AdviseDx SARS-CoV-2 IgG II assay. Roche and Abbott serological assays  
210 are widely used in clinical laboratories to detect SARS-CoV-2 antibodies worldwide.  
211 They detect the antibody against the RBD of the S antigen, yielding qualitative and

212 semi-quantitative results. MeDiPro is a Taiwan FDA-approved kit for quantifying S1-  
213 and RBD-binding antibodies; it assumes that data for S1 and RBD fusion proteins can  
214 accurately predict the NT titer. We used real NT titers (IU/mL) from BSL-3 as a  
215 standard to assess whether these serological assays reflect the neutralization titers based  
216 on the detection of antibodies against S1 and/or RBD. The highest correlation was  
217 observed between the titers obtained by the MeDiPro and the live SARS-CoV-2 NT  
218 assays ( $r = 0.9111$ ) (Figure 3A). Roche and Abbott RBD antibody titers also had good  
219 correlation coefficients of 0.7294 and 0.8466, respectively (Figure 3B and C). With  
220 respect to the live virus microneutralization assays, the Roche and Abbott serological  
221 assays can correctly detect RBD antibodies in all 77 NT-positive samples (Table 1),  
222 whereas MeDiPro produced six negative results. Among these six negative results, the  
223 NT titer of four samples is equal to 34.47 IU/mL, which is the limit of the detection in  
224 MeDiPro assay. Therefore, both the Roche and Abbot serological assays have 100%  
225 (95% CI, 95.3%-100%) sensitivity, followed by 92.2% (95% CI, 84.0%-96.4%)  
226 sensitivity for MeDiPro. However, MeDiPro can distinguish a greater proportion of  
227 NT-negative samples (40/43) than those of Roche (24/43) and Abbott (25/43). In terms  
228 of specificity, MeDiPro achieved a high specificity of 93% (95% CI, 81.4%-97.6%),  
229 which was much higher than of the Roche (55.8% [95% CI, 41.1%-69.6%]) and Abbott  
230 assays (58.1% [95% CI, 43.3%-71.6%]). Our results suggest that the MeDiPro SARS-

231 CoV-2 neutralization antibody assay is an effective option for detecting SARS-Cov-2  
232 neutralizing antibodies without requiring a live virus neutralization assay at a BSL-3  
233 laboratory.  
234

235 **Discussion**

236 Antibodies increase gradually within a few weeks after vaccination, and the timespan  
237 may vary among individuals (13, 14). Therefore, it is necessary to test neutralizing  
238 antibodies to determine whether protective antibodies will be elevated after vaccination.  
239 Vaccinated individuals may still have to take measures to avoid infection. Accordingly,  
240 such assays are very important for protecting vaccinated individuals as well as for the  
241 control and prevention of epidemics (15).

242       Anti-N antibodies may reveal whether vaccinated individuals were infected by the  
243 virus before or after the vaccination dose (16). For example, as shown in Figure 2B,  
244 one individual who received the Pfizer vaccine showed a dramatic increase in N to 556  
245 BAU/mL. S1 for the same individual, after the first and second doses, were 2,094 and  
246 1,240 BAU/mL, respectively. In the same individual, after the first and second doses,  
247 the RBD levels were 1,618 and 927 BAU/mL, respectively. It has been reported that  
248 prior infection with SARS-CoV-2 may boost B cells and significantly elevate antibody  
249 production (17, 18).

250       Roche and Abbott Covid-19 diagnostic kits are being used extensively in clinical  
251 laboratories (19-21). They are semi-quantitative and were originally designed to  
252 confirm an infected case. In this study, we utilized standard sera to develop an approach  
253 that utilizes these two kits to quantitate antibody titers after vaccination. The Pearson's

254 correlation coefficients ( $r$ ) between these antibody titers and neutralization antibody  
255 titers were 0.7294 and 0.8466, respectively. Titers obtained by MeDiPro, designed to  
256 detect neutralizing antibody titers, were highly correlated with titers obtained by live  
257 SARS-CoV-2 NT assays ( $r = 0.9111$ ).

258 IS was used to obtain neutralizing antibody titers in IU/mL and binding antibody  
259 titers in BAU/mL. We obtained GMTs of 1404.16 and 928.75 for neutralizing  
260 antibodies in serum samples from recipients of Moderna and Pfizer vaccines ( $n = 20$   
261 each) after two doses, respectively. These estimates may provide important information  
262 for vaccine developers implementing non-inferiority tests. Moreover, we compared  
263 three commercially available kits used for the detection of COVID-19 antibodies based  
264 on binding affinities to S1 and/or RBD. Our results demonstrated that antibody titers  
265 measured by commercial assays are strongly correlated with neutralizing antibody titers  
266 via IS calibration.

267

## 268 **Acknowledgements**

269 This work was financially supported by the Research Center for Emerging Viral  
270 Infections from The Featured Areas Research Center Program within the framework of  
271 the Higher Education Sprout Project by the Ministry of Education (MOE), Taiwan, the  
272 Ministry of Science and Technology (MOST), Taiwan (MOST 109-2634-F-182-001



273 and 109-2221-E-182-043-MY2), the Research Center for Epidemic Prevention Science  
274 by the MOST, Taiwan (MOST 109-2327-B-182-002), the Chang Gung Memorial  
275 Hospital (grant number BMRP367), and the National Institutes of Health USA grant  
276 U01 AI151698 for the United World Antiviral Research Network (UWARN).

277

#### 278 **Author contributions**

279 C.G.H, G.W.C. and S.R.S. designed the experiments. Y.A.K., S.Y.H., P.N.H., Y.T.L.  
280 and Y.C.L. conducted the live virus neutralization assay at BSL3 facility. K.T.L.,  
281 K.Y.Y., S.L.Y., C.P.C. and C.Y.C conducted the serological assay. Y.A.K., S.Y.H.,  
282 K.T.L. and C.G.H. analyzed the data. Y.A.K., K.T.L., G.W.C. and S.R.S. wrote the  
283 manuscript.

284

#### 285 **Declaration**

286 MeDiPro SARS-CoV-2 antibody ELISA was technology transferred from Research  
287 Center for Emerging Viral Infections, Chang Gung University, Taiwan. We herewith  
288 declare that MeDiPro, Roche, and Abbott did not financially support any research in  
289 Research Center for Emerging Viral Infections, Chang Gung University and Chang  
290 Gung Memorial Hospital, Taiwan.

291

292 **References**

- 293 1. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA,  
294 Subbarao K, Kent SJ, Triccas JA, Davenport MP. 2021. Neutralizing antibody  
295 levels are highly predictive of immune protection from symptomatic SARS-  
296 CoV-2 infection. *Nat Med* doi:10.1038/s41591-021-01377-8.
- 297 2. Chia WN, Zhu F, Ong SWX, Young BE, Fong SW, Le Bert N, Tan CW, Tiu  
298 C, Zhang J, Tan SY, Pada S, Chan YH, Tham CYL, Kunasegaran K, Chen MI,  
299 Low JGH, Leo YS, Renia L, Bertoletti A, Ng LFP, Lye DC, Wang LF. 2021.  
300 Dynamics of SARS-CoV-2 neutralising antibody responses and duration of  
301 immunity: a longitudinal study. *Lancet Microbe* 2:e240-e249.
- 302 3. Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber  
303 GR, Dull P, Plotkin SA. 2021. Evidence for antibody as a protective correlate  
304 for COVID-19 vaccines. *Vaccine* 39:4423-4428.
- 305 4. Bewley KR, Coombes NS, Gagnon L, McInroy L, Baker N, Shaik I, St-Jean  
306 JR, St-Amant N, Buttigieg KR, Humphries HE, Godwin KJ, Brunt E, Allen L,  
307 Leung S, Brown PJ, Penn EJ, Thomas K, Kulnis G, Hallis B, Carroll M,  
308 Funnell S, Charlton S. 2021. Quantification of SARS-CoV-2 neutralizing  
309 antibody by wild-type plaque reduction neutralization, microneutralization and  
310 pseudotyped virus neutralization assays. *Nat Protoc* 16:3114-3140.


- 311 5. Supasa P, Zhou D, Dejnirattisai W, Liu C, Mentzer AJ, Ginn HM, Zhao Y,  
312 Duyvesteyn HME, Nutalai R, Tuekprakhon A, Wang B, Paesen GC, Slon-  
313 Campos J, Lopez-Camacho C, Hallis B, Coombes N, Bewley KR, Charlton S,  
314 Walter TS, Barnes E, Dunachie SJ, Skelly D, Lumley SF, Baker N, Shaik I,  
315 Humphries HE, Godwin K, Gent N, Sienkiewicz A, Dold C, Levin R, Dong T,  
316 Pollard AJ, Knight JC, Klenerman P, Crook D, Lambe T, Clutterbuck E, Bibi  
317 S, Flaxman A, Bittaye M, Belij-Rammerstorfer S, Gilbert S, Hall DR,  
318 Williams MA, Paterson NG, James W, Carroll MW, Fry EE, Mongkolsapaya  
319 J, et al. 2021. Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by  
320 convalescent and vaccine sera. *Cell* 184:2201-2211 e7.
- 321 6. WHO/BS.2020.2403. 2020. Establishment of the WHO International Standard  
322 and Reference Panel for anti-SARS-CoV-2 antibody.
- 323 7. WHO/BS.2020.2402. 2020. Collaborative Study for the Establishment of a  
324 WHO International Standard for SARS-CoV-2 RNA.
- 325 8. Kristiansen PA, Page M, Bernasconi V, Mattiuzzo G, Dull P, Makar K,  
326 Plotkin S, Knezevic I. 2021. WHO International Standard for anti-SARS-  
327 CoV-2 immunoglobulin. *Lancet* 397:1347-1348.
- 328 9. Tan CW, Chia WN, Qin X, Liu P, Chen MI, Tiu C, Hu Z, Chen VC, Young  
329 BE, Sia WR, Tan YJ, Foo R, Yi Y, Lye DC, Anderson DE, Wang LF. 2020. A

- 330 SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated  
331 blockage of ACE2-spike protein-protein interaction. *Nat Biotechnol* 38:1073-  
332 1078.
- 333 10. Patel EU, Bloch EM, Clarke W, Hsieh YH, Boon D, Eby Y, Fernandez RE,  
334 Baker OR, Keruly M, Kirby CS, Klock E, Littlefield K, Miller J, Schmidt HA,  
335 Sullivan P, Piwowar-Manning E, Shrestha R, Redd AD, Rothman RE,  
336 Sullivan D, Shoham S, Casadevall A, Quinn TC, Pekosz A, Tobian AAR,  
337 Laeyendecker O. 2021. Comparative Performance of Five Commercially  
338 Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and  
339 Identify Individuals with High Neutralizing Titers. *J Clin Microbiol* 59.
- 340 11. Huynh A, Arnold DM, Smith JW, Moore JC, Zhang A, Chagla Z, Harvey BJ,  
341 Stacey HD, Ang JC, Clare R, Ivetic N, Chetty VT, Bowdish DME, Miller MS,  
342 Kelton JG, Nazy I. 2021. Characteristics of Anti-SARS-CoV-2 Antibodies in  
343 Recovered COVID-19 Subjects. *Viruses* 13.
- 344 12. Kyriakidis NC, Lopez-Cortes A, Gonzalez EV, Grimaldos AB, Prado EO.  
345 2021. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3  
346 candidates. *NPJ Vaccines* 6:28.
- 347 13. Goel RR, Apostolidis SA, Painter MM, Mathew D, Pattekar A, Kuthuru O,  
348 Gouma S, Hicks P, Meng W, Rosenfeld AM, Dysinger S, Lundgreen KA,

- 349 Kuri-Cervantes L, Adamski S, Hicks A, Korte S, Oldridge DA, Baxter AE,  
350 Giles JR, Weirick ME, McAllister CM, Dougherty J, Long S, D'Andrea K,  
351 Hamilton JT, Betts MR, Luning Prak ET, Bates P, Hensley SE, Greenplate  
352 AR, Wherry EJ. 2021. Distinct antibody and memory B cell responses in  
353 SARS-CoV-2 naive and recovered individuals following mRNA vaccination.  
354 *Sci Immunol* 6.
- 355 14. Pollard AJ, Bijker EM. 2021. A guide to vaccinology: from basic principles to  
356 new developments. *Nat Rev Immunol* 21:83-100.
- 357 15. Bartsch SM, O'Shea KJ, Ferguson MC, Bottazzi ME, Wedlock PT, Strych U,  
358 McKinnell JA, Siegmund SS, Cox SN, Hotez PJ, Lee BY. 2020. Vaccine  
359 Efficacy Needed for a COVID-19 Coronavirus Vaccine to Prevent or Stop an  
360 Epidemic as the Sole Intervention. *Am J Prev Med* 59:493-503.
- 361 16. Diao B, Wen K, Zhang J, Chen J, Han C, Chen Y, Wang S, Deng G, Zhou H,  
362 Wu Y. 2021. Accuracy of a nucleocapsid protein antigen rapid test in the  
363 diagnosis of SARS-CoV-2 infection. *Clin Microbiol Infect* 27:289 e1-289 e4.
- 364 17. Reynolds CJ, Pade C, Gibbons JM, Butler DK, Otter AD, Menacho K,  
365 Fontana M, Smit A, Sackville-West JE, Cutino-Moguel T, Maini MK, Chain  
366 B, Noursadeghi M, Network UKCIC, Brooks T, Semper A, Manisty C,  
367 Treibel TA, Moon JC, Investigators UKC, Valdes AM, McKnight A, Altmann

- 368 DM, Boyton R. 2021. Prior SARS-CoV-2 infection rescues B and T cell  
369 responses to variants after first vaccine dose. *Science*  
370 doi:10.1126/science.abh1282.
- 371 18. Anichini G, Terrosi C, Gandolfo C, Gori Savellini G, Fabrizi S, Miceli GB,  
372 Cusi MG. 2021. SARS-CoV-2 Antibody Response in Persons with Past  
373 Natural Infection. *N Engl J Med* 385:90-92.
- 374 19. Tan SS, Saw S, Chew KL, Wang C, Pajarillaga A, Khoo C, Wang W, Ali ZM,  
375 Yang Z, Chan YH, Tambyah P, Jureen R, Sethi SK. 2021. Comparative  
376 Clinical Evaluation of the Roche Elecsys and Abbott Severe Acute  
377 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Serology Assays for  
378 Coronavirus Disease 2019 (COVID-19). *Arch Pathol Lab Med* 145:32-38.
- 379 20. Harley K, Gunsolus IL. 2020. Comparison of the Clinical Performances of the  
380 Abbott Alinity IgG, Abbott Architect IgM, and Roche Elecsys Total SARS-  
381 CoV-2 Antibody Assays. *J Clin Microbiol* 59.
- 382 21. Speletas M, Kyritsi MA, Vontas A, Theodoridou A, Chrysanthidis T,  
383 Hatzianastasiou S, Petinaki E, Hadjichristodoulou C. 2020. Evaluation of Two  
384 Chemiluminescent and Three ELISA Immunoassays for the Detection of  
385 SARS-CoV-2 IgG Antibodies: Implications for Disease Diagnosis and  
386 Patients' Management. *Front Immunol* 11:609242.

387 **Figures and Tables**



388

389

390 **Figure 1. Neutralization serum titers in vaccinated individuals**

391 **(A)** NT<sub>50</sub> values for 120 serum samples from 20 recipients of Moderna mRNA-1273

392 and 20 recipients of Pfizer BNT162b2. **(B)** The calibration curve (standard curve) used

393 for the conversion of NT<sub>50</sub> values to the international standard units (IU/mL). Presented

394 are the results from an experiment in technical duplicate and error bars show the SD.

395 **(C)** The IU value for 120 serum samples (20 for the Moderna mRNA-1273 group and


396 20 for the Pfizer BNT162b2 group). The geometric mean titers (GMTs) with 95% CI

397 are shown pre-vaccination, after the first dose, and after the second dose.


398




## A Moderna



## B Pfizer



## C



399

400

401 **Figure 2. Antibody response in 120 serum samples from vaccinated individuals.**


402 The responses of antibodies against S1, RBD, and N protein were detected in 120 serum

403 samples from 20 individuals receiving Moderna mRNA-1273 (A) and 20 individuals

404 receiving Pfizer BNT162b2 vaccines (**B**). The geometric mean titers (GMTs) with 95%  
405 CI are shown pre-vaccination, after the first dose, and after the second dose. (**C**)  
406 Correlation between the live virus neutralization titer (IU/mL) and antibody binding  
407 unit (BAU/mL) in 120 serum samples. Vertical dashed lines indicate the limit of  
408 detection (NT = 34.47). The Pearson's correlation coefficients ( $r$ ) are provided for S1  
409 or RBD antibody responses to live virus neutralization titer (IU/mL).

410

411



412

413 **Figure 3. Correlation analysis of commercial serological assays against SARS-**  
414 **CoV-2 neutralizing antibody titers.**

415 Correlations between titers obtained by MeDiPro SARS-CoV-2 antibody ELISA (A),

416 Roche Elecsys<sup>®</sup> Anti-SARS-CoV-2 S assay (B), and Abbott AdviseDx SARS-CoV-2

417 IgG II assay (C) and live SARS-CoV-2 neutralization titers (IU/mL). The vertical

418 dashed line indicates the limit of detection (NT = 34.47 IU/mL). The horizontal dashed

419 lines indicate the cut-off values for MeDiPro (34.47 IU/mL), Roche (0.80 U/mL), and

420 Abbott (50.0 AU/mL). Correlations were performed in the Pearson's correlation

421 coefficients ( $r$ ).

422 **Table 1. Comparison of commercial serological assays with SARS-CoV-2**

423 **neutralizing antibody titer**

Total samples (120)	MeDiPro		Roche		Abbott	
Real NT	Positive	<sup>ψ</sup> Negative	Positive	<sup>c</sup> Negative	Positive	<sup>d</sup> Negative
Positive 77	71	<sup>ψ</sup> 6	77	0	77	0
<sup>a</sup> Negative 43	3	40	19	24	18	25
Sensitivity=TP/(TP+FN)	92.2% (84.0%-96.4%)		100% (95.3%-100%)		100% (95.3%-100%)	
Specificity=TN/(TN+FP)	93.0% (81.4%-97.6%)		55.8% (41.1%-69.6%)		58.1% (43.3%-71.6%)	
PPV=TP/(TP+FP)	95.9% (85.8%-98.9%)		80.2% (71.1%-87.0%)		81.1% (72.0%-87.7%)	
NPV=TN/(TN+FN)	87.0% (74.3%-93.9%)		100% (86.2%-100%)		100.0% (86.7%-100%)	

424 TP, true positive; FP, false positive; TN, true negative; FN, false negative; PPV,

425 positive predictive value; NPV, negative predictive value

426 <sup>a, b</sup> Negative < 34.37 IU/mL

427 <sup>c</sup> Negative < 0.80 U/mL

428 <sup>d</sup> Negative < 50.0 AU/mL

429 <sup>ψ</sup> Among the six negative samples, four samples have a neutralizing antibody titer of

430 34.37 IU/mL.

431

432

433

434 **Supplementary information**

435 **Supplementary Table 1. The NT<sub>50</sub> values of WHO international standard sera**

NIBSC Code	Research Reagent	WHO International Standard	WHO Reference Panel				
	NIBSC 20/130	NIBSC 20/136	NIBSC 20/268				
			High 20/150	Mid 20/148	low S, high N 20/144	Low 20/140	NC 20/142
Neutralizing Ab (IU/mL)	1300	1000	1473	210	95	44	—
Neutralizing Ab (NT <sub>50</sub> ) Test-1	446.8	223.89	398.11	79.43	20	<20	<20
Neutralizing Ab (NT <sub>50</sub> ) Test-2		486.97	370.88	100	19.95	<20	<20

436 NIBSC, National Institute for Biological Standards and Control; NT<sub>50</sub>, 50%

437 neutralization titer

438